Novartis and GlaxoSmithKline have returned to back a series B round that also attracted Singapore state-backed Vertex Ventures and university venturing fund Cambridge Innovation Capital.
UK-based biotechnology developer Bicycle Therapeutics raised £40m ($52m) in a series B round today backed by pharmaceutical firms Novartis and GlaxoSmithKline.
The round was led by Vertex Ventures HC, backed by Singapore’s sovereign wealth fund Temasek, and also included Cambridge Innovation Capital (CIC), the university venturing fund of University of Cambridge, as well as Longwood Fund, Atlas Venture and SV Life Sciences.
Novartis and GlaxoSmithKline invested through their respective corporate venturing subsidiaries Novartis Venture Fund and SR One.
